R&D | April 17, 2026
Revvity aims to accelerate breakthroughs in cancer research
Revvity is positioning its technologies as a connected engine for discovery
Revvity is positioning its technologies as a connected engine for discovery
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
The new outpatient-focused clinic is designed to address voice, airway and swallowing disorders through advanced diagnostics
Move amid evidence of widespread reporting gaps
Paves the way for next-gen ultra-precise gas sensing
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
Highlights Mirvetuximab-based regimen promise
Spread across nearly 4,500 sq. ft., the new clinic combines advanced dental technology, experienced specialists, and an Atithi-first care model
The license is valid for five years, effective from April 9, 2026
Each program will rely on partnerships between Novartis teams and local networks—including health authorities, community organizations and private sector groups
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
